Hazard ratios (HRs) with 95% confidence intervals (CIs) of the disease-specific mortality in clear-cell renal cell cancer (ccRCC) patients with low-, intermediate-, and high-immune cell score and HRs with 95% CI of the disease-specific mortality in ccRCC patients for CD3+ and CD8+ cell densities in the invasive margin (IM) and center of tumor (CT). This evidence concerns the gene CD8A and clear cell renal carcinoma.